Early age onset familial Mediterranean fever associated with compound heterozygote M680I /M694V mutation by Farajnia, S et al.
African Journal of Biotechnology Vol. 5 (19), pp. 1713-1716, 2 October 2006 
Available online at http://www.academicjournals.org/AJB 







Full Length Research Paper 
 
Early age onset familial Mediterranean fever associated 
with compound heterozygote M680I /M694V mutation 
 
Safar Farajnia1,2*, Ailar Nakhlband1, Mandana Rafeey3 and Kazem Sakha3 
 
1Drug Applied Research Center, Tabriz University of Medical Science 
2Biotechnology Research center, Tabriz University of Medical Science  
3Department of Medicine, Tabriz University of Medical Science, Daneshgah Ave., Tabriz. Iran. 
 
Accepted 31 August, 2006 
 
Familial Mediterranean fever (FMF) is an autosomal recessive genetic disorder characterized by acute 
episodes of fever accompanied by severe abdominal pain, pleurisy, arthritis, and skin rash. The clinical 
variability of the disease has been mainly attributed to MEFV gene allelic heterogeneity and partly to the 
influence of additional genetic and/or environmental factors. We present a 6-month-old boy who 
suffered from recurrent fever accompanied by abdominal pain and skin rashes. Molecular screening by 
polymerase chain reaction (PCR) and sequencing for common mutations causing FMF revealed 
presence of a 694V/680I compound heterozygote mutation in exon 10 of the related gene. This is the 
first report of early onset and severe phenotype FMF case associated with a 694V/680I compound 
heterozygote mutation. 
 





Familial Mediterranean fever (FMF; MIM249100) is an 
autosomal recessive disease characterized by recurrent 
attacks of fever and peritonitis, pleuritis, arthritis or 
erysipelas-like erythema. The most serious complication 
of FMF is the development of systemic amyloidosis, 
ultimately leading to renal failure (Samuels et al., 1998). 
Symptoms can appear during the first decade of life and 
more than 80% of patients experience the disease during 
childhood and adolescence. A typical attack of disease 
consists of fever and serositis lasting for 1- 3 days, with a 
spontaneous recovery. Between attacks FMF patients 
are usually free of symptoms. The severity and frequency 
of the attacks varies between patients and the male to 
female ratio is considered to be 1.2:1 (Tunca et al., 
2005).  
FMF predominantly affects the population surrounding 
the Mediterranean basin (Ben-Chetrit and Levy, 1998). 
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Armenians, and Sephardic Jews (Bakkaloglu, 2003). 
However, cases from other ethnic groups in other parts of 
the world are increasingly being reported. The prevalence 
of FMF in Iranian population has not well defined but in 
Iranian Jews it has been reported to be about 6% 
(Stoffman et al., 2000). 
Until recently, the diagnosis of FMF was based on 
clinical manifestations, ethnicity, family history and 
response to colchicines. In 1992, the gene responsible 
for FMF was localized on the short arm of chromosome 
16 (Pras et al., 1992) and in 1997, two independent 
groups cloned the specific gene for FMF (MEFV) (The 
French FMF Consortium and The International FMF 
Consortium 1997). The gene encodes pyrin/marenostrin 
protein that is a member of the RoRet gene family and is 
expressed predominantly in granulocytes. On the basis of 
the FMF phenotype, pyrin is likely to be a negative 
regulator of granulocyte-mediated inflammation (Pars 
1998). To date, more than 50 FMF associated pyrin gene 
mutations have been identified; most of them are mapped 
on exon 10 and four of these missense mutations (M680I, 
M694V, M694I, and V726A), are responsible for about 
70-86% of  mutations  depending  on  ethnic group. It has  




Table 1. Results of genetic analysis for common MEFV 
gene mutations. 
 
Subject 694V 694I 680I 726A 
Child M/N N/N M/N N/N 
Father M/N N/N N/N N/N 






Figure 1. Pedigree illustrating mode of mutation inheritance. Open 
boxes are related to parents that is asymptomatic FMF gene carrier, 
black box is related to child with FMF due to M694V/M680I 




been shown that some of the MEFV gene mutations have 
low penetrance (E148Q, P396S) (Cazeneuve et al., 
1999), whereas some (V726A) lead to a milder disease 
(Aksen-tijevich et al., 1999). The M694V mutation is the 
most prevalent mutation, known to be associated with a 
severe FMF and frequently seen among people suffering 
from amyloidosis in homozygote state (Livneh et al., 
1999; Shohat et al., 1999). In this report we present 
mutation analysis of an Iranian patient with early onset 
and severe FMF, which contain a 694V/680I compound 
heterozygote genotype.   
 
 




A six-month-old male baby presented with periodic attacks of fever, 
abdominal pain, and erysipelas-like erythema. His periodic attacks 
was noted at 4th month for the first time, which was appeared as 
fever of up to 40°C about once a week lasting 1-2 day and 
accompanied with abdominal pain in most cases. The patient's 
parents never had periodic febrile attacks and there was no history 
of consanguineous marriage. Chest and abdominal imaging failed 
to detect any abnormalities. Laboratory findings at the time of 
febrile attacks were as follows: Hemoglobin 12.8 g/dl, white blood 
cell count 15300/L (68% granulocytes, 26% lymphocytes, 4% band 
and 2% monocytes), platelet count 320000/L, erythrocyte 
sedimentation rate 54 mm/h, fibrinogen level 255 mg/dl (normal: 
200-400 mg/dl) and C-reactive 3+. Blood chemistry and urinalysis 
were normal. Autoantibodies, including ANA and RF were negative. 





remarked clinical efficacy. Treatment with 0.5 mg/day of colchicines 
showed no significant improvement but 1 mg/day of colchicines was 
associated with good therapeutic response.  
 
 
Genetic analysis  
 
Molecular testing was carried out on DNA extracted from peripheral 
blood leukocytes of the patient and his parents by standard 
methods (Sambrook et al., 1989). The four common mutations 
(Met694Val, Met680Ile, Val726Ala, and Met694Ile) were 
investigated with the aid of amplification refractory mutation system 
(ARMS) using primers designed to amplify the normal or altered 
alleles. Each set of primers consisted of three oligonucleotides, their 
sequences were as follows: 694V common: 5'-
TATCATTGTTCTGGGCTC-3', mutant: 5'-
TGGTACTCATTTTCCTTCAC-3', normal: 5'-





694I common: 5'-TATCATTGTTCTGGGCTC-3', normal: 5'-
CTGGTACTCATTTTCCTTC-3', mutant: 5'-
CTGGTACTCATTTTCCTTT-3', and 680I: common: 5'- 
GGAAACAAGTGGGAGAGGCTGC-3', mutant 5'- 
GTAGCCATTCTCTAGCGACAGTGCC -3', normal: 5'- 
GTAGCCATTCTCTAGCGACAGTGCG -3' . The primers for 
amplification of complete exon 10 were as follow: E10 forward; 5’-
CCCATGGACCCCTACCTAGG- 3’; 
E10-Reverse 5’-AAGAGAGATGCAGTGTTGGGC-3’. Polymerase 
chain reaction (PCR) were carried out in 25 microliter reaction 
volumes containing 100 ng genomic DNA, 25 pmols primers, 0.2 
mM dNTPs, 2.5 µL reaction buffer (100 mM Tris pH 8.3, 500 mM 
KCl, 15 mM MgCl2) and 1 U Taq DNA polyemerase (Fermentas). 
Cycling condition were 94ºC 4 min, followed by 30 cycles of 94ºC 1 
min, 58ºC 30 s, 72ºC 30 s and a final extension of 72ºC 5 min. PCR 
products were separated by electrophoresis on a 1.5% agarose gel. 
Ethidium bromide staining of the agarose gel was used to detect the 
amplified fragments. Entire amplified exon 10 was subjected for 
sequencing by dideoxy method.  
 
 
RESULTS AND DISCUSSION 
 
The results of genetic analysis have shown in Table 1 
and Figure 1. Genetic analysis using ARMS-PCR 
revealed that the patient was compound heterozygote for 
694V/680I mutation and his father and mother were 
heterozygote for 694V and 680I mutation respectively. 
Sequencing of the complete exon 10 coding region 
confirmed the results of ARMS-PCR and did not show 
any other mutation. 
FMF is a genetic condition inherited in an autosomal 
recessive fashion. Mutations in the MEFV gene (short for 
Mediterranean fever) on chromosome number 16 are the 
underlying cause of FMF (The French FMF Consortium, 
1997). The clinical characteristics of FMF including fever, 
peritonitis, pleurisy, rashes, arthritis, and occurrence of 
amyloidosis are variable in their pattern, frequency, 
intensity and age of onset. Extensive attempts have been 
spent to understand the base of such variability and, 
types of mutations, ethnic background, additional genetic 





this phenotype difference. Initial phenotype–genotype 
studies suggest the presence of a correlation between 
some mutations and severity of the disease (Pras et al., 
1997; Dewalle et al., 1998). Patients who are homozy-
gous for M694V mutation are reported to have 
particularly severe FMF disease and possibly a greater 
propensity to develop AA amyloidosis (Cazeneuve et al., 
1999; Shohat et al., 1999; Dewalle et al., 1998). Recent 
studies reported that M694V are the most common 
mutation in those developing secondary amyloidosis and 
that the M694V mutation is an important factor in 
predicting the development of amyloidosis (Balci et al., 
2002). Appearance of FMF in which MEFV mutation 
affect only a single allele remains a subject of 
controversy. While there are repots indicating FMF 
disease in individuals are heterozygote for known MEFV 
mutations (suggest an autosomal dominant inheritance 
(Yuval et al., 2001), the presence of mutations without 
phenotypic association are relatively common observa-
tion and referred as phenotype III FMF (Kogan et al., 
2001). The M680I mutation, one of the other common 
mutations prevalently seen in Armenian patients, was 
suggested to be associated with a milder phenotype 
(Pars, 1998)  
The patient described herein both has inappropriate 
ethnic background and their clinical presentations spec-
ially the age of onset were unusual. The tests for detec-
ting common mutations responsible for FMF showed that 
he was compound heterozygote for the M694V/M680I 
mutation. The father and mother of the patient that were 
heterozygote for 694V and 680I mutations respectively 
have never experienced clinical signs of FMF, whereas in 
child the association of these two mutations has lead to a 
severe FMF. It has been shown that many heterozygote 
individuals including the father of our patient with 694V 
mutation in one allele did not show clinical expression of 
FMF. In the other hand clinical manifestations associated 
with mutation M680I are considered less severe. Our 
data indicate that the association of these two mutations 
even in compound heterozygote form might lead to a 
severe FMF characterized by the early age onset and 
high frequency of painful episodes. 
Although established clinical criteria for diagnosis of 
FMF exist (Livneh et al., 1997), many patients remain 
undiagnosed because of rather nonspecific symptoms. 
Therefore, molecular genetic analysis could substantially 
improve early and correct diagnosis of FMF and helps for 
making decision for initiation of lifelong prophylactic 
treatment with colchicine which is known to prevent the 
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